ArticleAccounts of chemical research2022
Disrupting Crystal Growth through Molecular Recognition: Designer Therapies for Kidney Stone Prevention.
Article in Accounts of chemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Mechanistic Insights into Molecular Modifiers That Promote Urate Crystallization through Solute Assembly Regulation.JACS Au · 2026Article
- Ferulic andRSC advances · 2026Article
- Supplemental exposure to polystyrene nanoplastics synergistically amplifies calcium oxalate crystal-induced injury to renal tubular epithelium, accelerating the formation of calcium oxalate kidney stones.Particle and fibre toxicology · 2026Article
- Effect of Small Molecular Additives on Growth Rates of Molecular Crystals from the Melt near Glass-Transition Temperature.Crystal growth & design · 2026Article
- Kidney Stones as Minerals: How Methods from Geology Could Inform Urolithiasis Treatment.Journal of clinical medicine · 2025Review
- Nineteenth Century Amorphous Calcium Carbonate.Crystal growth & design · 2024Review
- Discovery of l-Lysine Dioxalate (LH1513) as a Novel Inhibitor of Calcium Oxalate Crystallization for Hyperoxaluria.ACS medicinal chemistry letters · 2024Article
- Structure-activity relationships and pharmacokinetic evaluation of L-cystine diamides as L-cystine crystallization inhibitors for cystinuria.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2024Article
- 8-l-Cystinyl Bis(1,8-diazaspiro[4.5]decane) as an Orally Bioavailable l-Cystine Crystallization Inhibitor for Cystinuria.ACS medicinal chemistry letters · 2024Article
- Understanding formation processes of calcareous nephrolithiasis in renal interstitium and tubule lumen.Journal of cellular and molecular medicine · 2024Review
- Chemical Modification of Tiopronin for Dual Management of Cystinuria and Associated Bacterial Infections.ACS applied materials & interfaces · 2023Article
- CarboxymethylatedBiomolecules · 2023Article
- An overview of global research landscape in etiology of urolithiasis based on bibliometric analysis.Urolithiasis · 2023Review
- Application of metabolomics in urolithiasis: the discovery and usage of succinate.Signal transduction and targeted therapy · 2023Article
- Oxalate as a potent promoter of kidney stone formation.Frontiers in medicine · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aberrant crystallization within the human body can lead to several disease states or adverse outcomes, yet much remains to be understood about the critical stages leading to these events, which can include crystal nucleation and growth, crystal aggregation, and the adhesion of crystals to cells. Kidney stones, which are aggregates of single crystals with physiological origins, are particularly illustrative of pathological crystallization, with 10% of the U.S. population experiencing at least one stone occurrence in their lifetimes. The human record of kidney stones is more than 2000 years old, as noted by Hippocrates in his renowned oath and much later by Robert Hooke in his treatise
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.